David A. Scheinberg: Publications

David A. Scheinberg: Publications

Share
Share

View a full listing of David A. Scheinberg: Publications’ journal articles.

  1. Dao T, Yan S, Veomett N, Pankov D, Zhou L, Korontsvit T, Scott A, Whitten J, Maslak P, Casey E, Tan T, Liu H, Zakhaleva V, Curcio M, Doubrovina E, O’Reilly RJ, Liu C, Scheinberg DA. Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. Science translational medicine. 2013;5(176):176ra33. Doi: 10.1126/scitranslmed.3005661. PubMed PMID: 23486779; PMCID: PMC3963696.
  2. Dao T, Pankov D, Scott A, Korontsvit T, Zakhaleva V, Xu Y, Xiang J, Yan S, de Morais Guerreiro MD, Veomett N, Dubrovsky L, Curcio M, Doubrovina E, Ponomarev V, Liu C, O’Reilly RJ, Scheinberg DA. Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1. Nature biotechnology. 2015;33(10):1079-86. Doi: 10.1038/nbt.3349. PubMed PMID: 26389576; PMCID: PMC4600043.
  3. Gardner TJ, Lee JP, Bourne CM, Wijewarnasuriya D, Kinarivala N, Kurtz KG, Corless BC, Dacek MM, Chang AY, Mo G, Nguyen KM, Brentjens RJ, Tan DS, Scheinberg DA. Engineering CAR-T Cells to Activate Small-Molecule Drugs in situ.  Nat. Chem Biol, 2021 DOI: 10.1038/s41589-021-00932-1. PMID: 34969970; PMCID: PMC9152922.
  4. Brea EJ, Oh CY, Manchado E, Budhu S, Gejman RS, Mo G, Mondello P, Han JE, Jarvis CA, Ulmert D, Xiang Q, Chang AY, Garippa RJ, Merghoub T, Wolchok JD, Rosen N, Lowe SW, Scheinberg DA. Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells. Cancer immunology research. 2016; 4(11):936-47. Doi: 10.1158/2326-6066.CIR-16-0177. PubMed PMID: 27680026; PMCID: PMC5110210.
  5. Gejman RS, Chang AY, Jones HF, DiKun K, Hakimi AA, Schietinger A, Scheinberg DA. Rejection of immunogenic tumor clones is limited by clonal fraction. eLife, 2018; 7:e41090. DOI: https://doi.org/10.7554/eLife.41090. PMID: 30499773; PMCID: 6269121.
  6. Gejman RS, Jones HF, Klatt MG, Chang AY, Oh CY, Chandran SS, Korontsvit T, Zakahleva V, Dao T, Klebanoff CA, Scheinberg DA. Identification of the Targets of T-cell Receptor Therapeutic Agents and Cells by Use of a High-Throughput Genetic Platform. Cancer Immunol Res. 2020 May;8(5):672-684. doi: 10.1158/2326-6066.CIR-19-0745. Epub 2020 Mar 17. PMID: 32184297; PMC7310334.
  7. McDevitt MR, Ma D, Lai LT, Simon J, Borchardt P, Frank RK, Wu K, Pellegrini V, Curcio MJ, Miederer M, Bander NH, Scheinberg DA. Tumor therapy with targeted atomic nanogenerators. Science. 2001; 294:1537-1540. DOI: 10.1126/science.1064126. PMID:11711678.
  8. Maslak PG, Dao T, Bernal Y, Chanel S, Zhang R, Frattini M, Rosenblat T, Jurcic J, Brentjens R, Arcila ME, Rampal R, Park J. Douer D, Katz LM, Sarlis NJ, Tallman M, Scheinberg DA.  Prolonged survival in acute myeloid leukemia with galinpepimut-S, a WT1 peptide vaccine, given after achievement of CR1. Blood Advances. 2018; PMID: 29386195; PMCID: PMC5812332
  9. Mulvey JJ, Villa CH, McDevitt MR, Escorcia FE, Casey E, Scheinberg DA. Self-assembly of carbon nanotubes and antibodies on tumours for targeted amplified delivery. Nature Nanotechnology. 2013; 8(10):763-71. PMID: 2407702; PMCID: PMC3798027.
  10. Alidori S, Akhavein N, Thorek DL, Behling K, Romin Y, Queen D, Beattie BJ, Manova-Todorova K, Bergkvist M, Scheinberg DA, McDevitt MR. Targeted fibrillar nanocarbon RNAi treatment of acute kidney injury. Science Translational Medicine. 2016; 8(331):331ra39. PMID: 27009268; PMCID: PMC5004247.
  11. Rafiq S, Purdon TJ, Daniyan AF, Koneru M, Dao T, Liu C, Scheinberg DA, Brentjens RJ. Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen. Leukemia. 2017. Doi: 10.1038/leu.2016.373. PMID: 27924074 PMCID: PMC5495623.